Skip to main content
DIACEUTICS PLC logo

DIACEUTICS PLC — Investor Relations & Filings

Ticker · DXRX ISIN · GB00BJQTGV64 LEI · 213800VEWQBB39ZB8J81 IL Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 278 across all filing types
Latest filing 2026-05-26 Earnings Release
Country GB United Kingdom
Listing IL DXRX

About DIACEUTICS PLC

https://www.diaceutics.com/

Diaceutics PLC is a data analytics and end-to-end services provider focused on the development and commercialization of precision medicine diagnostics. The company supports pharmaceutical and biotech clients by providing solutions to improve the diagnostic testing ecosystem, aiming to ensure patients receive the correct personalized treatment. Its primary offering is DXRX, The Diagnostic Network®, a diagnostic commercialization platform for precision medicine. DXRX facilitates collaboration among stakeholders, including laboratories and pharmaceutical companies, in a secure marketplace and provides access to real-world diagnostic testing data. This integrated platform is designed to streamline the launch and adoption of new precision medicines.

Recent filings

Filing Released Lang Actions
Final Results
Earnings Release Classification · 91% confidence The document is a Regulatory News Service (RNS) announcement titled “Diaceutics FY 2025 Results,” published as an RNS (5747F). It provides a high‐level financial summary, key performance metrics (revenue growth, EBITDA, ARR, order book), summary financial tables, and commentary (CEO, Chair’s review). It reads like a press release of full‐year results, including highlights and outlook, and invites investors to an analyst presentation. It does not contain full audited financial statements or notes as in an Annual Report (10-K), nor is it a simple report publication notice. This best matches an Earnings Release (ER): the initial announcement of periodical (in this case full‐year) financial results. FY 2025
2026-05-26 English
Notice of Results
Report Publication Announcement Classification · 85% confidence The document is an RNS announcement entitled “Notice of Results & Presentations.” It contains no substantive financial data but rather provides the date for the audited final results announcement (26 May 2026) and details of an upcoming analyst webinar. It does not include the actual report or financial figures, only notice of its forthcoming publication. Under the “menu vs meal” rule, this is a Report Publication Announcement rather than the report itself.
2026-05-13 English
Holding(s) in Company
Major Shareholding Notification Classification · 95% confidence The document is a TR-1 standard form notifying the crossing of a major shareholding threshold by Danske Bank A/S in Diaceutics PLC. It clearly details the percentage of voting rights before and after the threshold event, the shareholder chain, and is labeled “notification of major holdings.” This matches the definition for a Major Shareholding Notification.
2026-05-12 English
PDMR Shareholding/Share Incentive Plan and TVRs
Director's Dealing Classification · 100% confidence The document is a notification from Diaceutics PLC regarding share transactions by persons discharging managerial responsibilities (PDMRs) under the company's Share Incentive Plan (SIP). It details ongoing non-discretionary purchases of shares and matched share awards for specific executives. The document includes transaction dates, volumes, prices, and regulatory references such as Article 19(1) of Regulation (EU) No. 596/2014, which pertains to insider transaction disclosures. There is no financial performance data, earnings information, or report publication mentioned. The content fits the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives (insider trades).
2026-05-05 English
Block Listing Return
Share Issue/Capital Change Classification · 90% confidence The document is an RNS announcement titled “Block Listing Return” under Schedule 6 of the AIM Rules, detailing the share incentive plans (SIP, ESOP, USOP), the number of shares issued/allotted during the period, block scheme balances and total shares in issue. This constitutes an announcement of share issuance/capital change rather than the report of the scheme itself or any AGM materials. Therefore it matches the Share Issue/Capital Change category (SHA).
2026-04-07 English
PDMR Shareholding/SIP & Total Voting Rights
Director's Dealing Classification · 97% confidence The document is an RNS announcement under the Market Abuse Regulation (Article 19(1) EU No. 596/2014) detailing ongoing non-discretionary share purchases and matched share awards by PDMRs (senior executives) under the Company’s Share Incentive Plan. It reports personal share transactions by directors/executives (insider trades), matching the definition of Director’s Dealing (Code: DIRS).
2026-04-01 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.